Skip to main content
Quest Diagnostics

Clinicopathologic Features of Antibrush Border Antibody Disease

Clinicopathologic Features of Antibrush Border Antibody Disease

Authors: Murphy JD, Caza TN, Cassol CA, Storey A, Ambruzs JM, Boils C, Walker PD, Sharma S, Messias N, Hennigar R, Andeen NK, VanBeek C, Palmer M, Sankar L, Sanghi P, Dinesh K, Dicker L, Urisman A, Larsen CP

Citation: Kidney Int Rep. 2023 Nov 19;9(2):370-382. doi: 10.1016/j.ekir.2023.11.008.

Specialties: Cardiology, Cardiovascular disease, Endocrinology, Immunology

Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content 

Publication
Association between liver and chronic kidney disease on hemoglobin A1c concentrations
Publication
Pseudoendocrine Sarcoma: Clinicopathologic, Molecular, and Epigenetic Features of One Case
On-Demand Webinar
Reducing cardiovascular risk in the patient with elevated triglycerides
Test FAQ
Kidney Profile

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.